BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Macedo AF, Bell J, Mccarron C, Conroy R, Richardson J, Scowcroft A, Sunderland T, Rotheram N. Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink. Thrombosis Research 2015;136:250-60. [DOI: 10.1016/j.thromres.2015.06.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Faircloth JM, Miner KM, Alsaied T, Nelson N, Ciambarella J, Mizuno T, Palumbo JS, Vinks AA, Veldtman GR. Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients. J Thromb Thrombolysis 2017;44:38-47. [DOI: 10.1007/s11239-017-1499-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
2 Roseau C, Richard C, Renet S, Kowal C, Eliahou L, Rieutord A, Chaumais MC. Evaluation of a program of pharmaceutical counseling for French patients on oral anticoagulant therapy. Int J Clin Pharm 2020;42:685-94. [PMID: 31933106 DOI: 10.1007/s11096-020-00964-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Zawawi NA, Abdul Halim Zaki I, Ming LC, Goh HP, Zulkifly HH. Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation. Front Cardiovasc Med 2021;8:736143. [PMID: 34869639 DOI: 10.3389/fcvm.2021.736143] [Reference Citation Analysis]
4 Limdi NA, Brown TM, Shendre A, Liu N, Hill CE, Beasley TM. Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users. Pharmacogenet Genomics 2017;27:347-55. [PMID: 28806200 DOI: 10.1097/FPC.0000000000000298] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
5 Kataruka A, Kong X, Haymart B, Kline-Rogers E, Almany S, Kozlowski J, Krol GD, Kaatz S, McNamara MW, Froehlich JB, Barnes GD. SAMe-TT2R2 predicts quality of anticoagulation in patients with acute venous thromboembolism: The MAQI2 experience. Vasc Med 2017;22:197-203. [PMID: 28145152 DOI: 10.1177/1358863X16682863] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
6 Urbonas G, Valius L, Šakalytė G, Petniūnas K, Petniūnienė I. The Quality of Anticoagulation Therapy among Warfarin-Treated Patients with Atrial Fibrillation in a Primary Health Care Setting.Medicina (Kaunas). 2019;55. [PMID: 30650565 DOI: 10.3390/medicina55010015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Liyew Z, Tadesse A, Bekele N, Tsegaye T. Evaluation of Anticoagulation Control among Patients Taking Warfarin in University of Gondar Hospital, Northwest Ethiopia. Adv Hematol 2021;2021:7530997. [PMID: 34970315 DOI: 10.1155/2021/7530997] [Reference Citation Analysis]
8 Mwita JC, Francis JM, Oyekunle AA, Gaenamong M, Goepamang M, Magafu MGMD. Quality of Anticoagulation With Warfarin at a Tertiary Hospital in Botswana.Clin Appl Thromb Hemost. 2018;24:596-601. [PMID: 29258394 DOI: 10.1177/1076029617747413] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
9 Al Ammari M, AlThiab K, AlJohani M, Sultana K, Maklhafi N, AlOnazi H, Maringa A. Tele-pharmacy Anticoagulation Clinic During COVID-19 Pandemic: Patient Outcomes. Front Pharmacol 2021;12:652482. [PMID: 34566632 DOI: 10.3389/fphar.2021.652482] [Reference Citation Analysis]
10 Liberato NL, Marchetti M. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review. Expert Review of Pharmacoeconomics & Outcomes Research 2016;16:221-35. [DOI: 10.1586/14737167.2016.1147351] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
11 Keller K, Göbel S, Ten Cate V, Panova-Noeva M, Eggebrecht L, Nagler M, Coldewey M, Foebel M, Bickel C, Lauterbach M, Espinola-Klein C, Lackner KJ, Cate HT, Münzel T, Wild PS, H Prochaska J. Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism-Results from the thrombEVAL Study. J Clin Med 2020;9:E3281. [PMID: 33066188 DOI: 10.3390/jcm9103281] [Reference Citation Analysis]
12 McAuliffe GN, De Silva F, Upton A, Chan G. International normalised ratio monitoring in the community populations of the Auckland and Northland regions of New Zealand: time in therapeutic range and frequency of testing. Intern Med J 2018;48:1487-91. [PMID: 29992735 DOI: 10.1111/imj.14032] [Reference Citation Analysis]
13 Fung KP, Chan KH, Ng V, Tsui PT, You JHS. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients. Cardiovasc Drugs Ther 2019;33:331-7. [PMID: 30888571 DOI: 10.1007/s10557-019-06872-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 van Miert JHA, Bos S, Veeger NJGM, Meijer K. Clinical usefulness of the SAMe-TT2R2 score: A systematic review and simulation meta-analysis. PLoS One 2018;13:e0194208. [PMID: 29534092 DOI: 10.1371/journal.pone.0194208] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
15 Camilleri E, van Rein N, van der Meer FJM, Nierman MC, Lijfering WM, Cannegieter SC; Dutch Covid‐19 & Thrombosis Coalition. Stability of vitamin K antagonist anticoagulation after COVID-19 diagnosis. Res Pract Thromb Haemost 2021;5:e12597. [PMID: 34667920 DOI: 10.1002/rth2.12597] [Reference Citation Analysis]
16 Avarello I, Bianchi S, Toschi V, Zighetti ML, Faioni EM. Time in therapeutic range is lower in women than in men and is not explained by differences in age or comorbidity. Thromb Res 2021;203:18-21. [PMID: 33901765 DOI: 10.1016/j.thromres.2021.04.011] [Reference Citation Analysis]
17 Djalali S, Valeri F, Gerber B, Meli DN, Senn O. Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials. Clin Appl Thromb Hemost 2017;23:685-95. [PMID: 27056934 DOI: 10.1177/1076029616642514] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
18 Ambrus D, Reisman J, Rose A. The impact of new-onset cancer among veterans who are receiving warfarin for atrial fibrillation and venous thromboembolism. Thrombosis Research 2016;144:21-6. [DOI: 10.1016/j.thromres.2016.05.028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
19 Lim MS, Nandurkar D, Jong I, Cummins A, Tran H, Chunilal S. Incidence of residual perfusion defects by lung scintigraphy in patients treated with rivaroxaban compared with warfarin for acute pulmonary embolism. J Thromb Thrombolysis 2020;49:220-7. [DOI: 10.1007/s11239-019-01944-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Reading SR, Black MH, Singer DE, Go AS, Fang MC, Udaltsova N, Harrison TN, Wei RX, Liu IA, Reynolds K; ATRIA-CVRN Investigators. Risk factors for medication non-adherence among atrial fibrillation patients. BMC Cardiovasc Disord 2019;19:38. [PMID: 30744554 DOI: 10.1186/s12872-019-1019-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
21 Gungorer B. Risk factors associated with warfarin overdose and complications related to warfarin overdose in the emergency department. Drug Chem Toxicol 2021;:1-7. [PMID: 33494629 DOI: 10.1080/01480545.2020.1868493] [Reference Citation Analysis]
22 van Miert JHA, Veeger NJGM, Meijer K. Is the time in therapeutic range on coumarins predicted by previous time in therapeutic range? Res Pract Thromb Haemost 2020;4:604-9. [PMID: 32548559 DOI: 10.1002/rth2.12328] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Beyene K, Chan AHY, Näslund P, Harrison J. Patient-related factors associated with oral anticoagulation control: a population-based cohort study. Int J Pharm Pract 2021:riab041. [PMID: 34302345 DOI: 10.1093/ijpp/riab041] [Reference Citation Analysis]
24 Manzato RO, Ciol MA, Bolela F, Dessotte CAM, Rossi LA, Dantas RAS. The effect of reinforcing an educational programme using telephone follow-up on health-related quality of life of individuals using warfarin: A randomised controlled trial. J Clin Nurs 2021;30:3011-22. [PMID: 33893673 DOI: 10.1111/jocn.15811] [Reference Citation Analysis]
25 Botton MR, Viola PP, Meireles MR, Bruxel EM, Zuchinali P, Bandinelli E, Rohde LE, Leiria TLL, Salamoni JYY, Garbin AP, Hutz MH. Identification of environmental and genetic factors that influence warfarin time in therapeutic range. Genet Mol Biol 2020;43:e20190025. [PMID: 32052826 DOI: 10.1590/1678-4685-GMB-2019-0025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Zulkifly H, Cheli P, Lutchman I, Bai Y, Lip GYH, Lane DA. Anticoagulation control in different ethnic groups receiving vitamin K antagonist therapy for stroke prevention in atrial fibrillation. Thromb Res 2020;192:12-20. [PMID: 32416364 DOI: 10.1016/j.thromres.2020.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Lin KJ, Singer DE, Glynn RJ, Blackley S, Zhou L, Liu J, Dube G, Oertel LB, Schneeweiss S. Prediction Score for Anticoagulation Control Quality Among Older Adults. J Am Heart Assoc 2017;6:e006814. [PMID: 28982676 DOI: 10.1161/JAHA.117.006814] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
28 Lee SL, Ong TJ, Mazlan-Kepli W, Mageswaran A, Tan KH, Abd-Malek AM, Cronshaw R. Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. World J Cardiol 2021; 13(9): 483-492 [PMID: 34621493 DOI: 10.4330/wjc.v13.i9.483] [Reference Citation Analysis]
29 Kamphuisen PW, Lee AYY, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. J Thromb Haemost. 2018;16:1069-1077. [PMID: 29573330 DOI: 10.1111/jth.14007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
30 Palareti G, Antonucci E, Migliaccio L, Erba N, Marongiu F, Pengo V, Poli D, Testa S, Tosetto A, Tripodi A, Moia M; centers participating in the FCSA-START-Register (The ISCOAT 2016 study: Italian Study on Complications of Oral Anticoagulant Therapy-2016). Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. Intern Emerg Med 2017;12:1109-19. [PMID: 28501909 DOI: 10.1007/s11739-017-1678-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
31 Abdou JK, Auyeung V, Patel JP, Arya R. Adherence to long-term anticoagulation treatment, what is known and what the future might hold. Br J Haematol 2016;174:30-42. [DOI: 10.1111/bjh.14134] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
32 Johnson ME, Lefèvre C, Collings SL, Evans D, Kloss S, Ridha E, Maguire A. Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. BMJ Open 2016;6:e011471. [PMID: 27678530 DOI: 10.1136/bmjopen-2016-011471] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]